VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

HspX–PPE44–EsxV

Vaccine Information

Vaccine Name: HspX–PPE44–EsxV
Target Pathogen: Mycobacterium tuberculosis
Target Disease: Tuberculosis
Type: Subunit vaccine
Status: Research
Host Species for Licensed Use: Mouse
Antigen: Fusion protein composed by HspX, PPE44 and EsxV (Mansury et al., 2019).
hspX gene engineering:
- Type: Fusion Protein
- Description: This is use in fusion protein preparation (Mansury et al., 2019).
- Detailed Gene Information: Click Here.
esxV gene engineering:
- Type: Fusion Protein
- Description: This is use in fusion protein preparation (Mansury et al., 2019).
- Detailed Gene Information: Click Here.
PPE44 gene engineering:
- Type: Fusion Protein
- Description: This is use in fusion protein preparation (Mansury et al., 2019).
- Detailed Gene Information: Click Here.
Adjuvant: liposome-based vaccine adjuvant
- Adjuvant name: liposome-based vaccine adjuvant
- VO adjuvant ID: VO_0000366
- Description: Adjuvant lipo-ae(DOTAP/CHOL) is use in this vaccine(Mansury et al., 2019).
Preparation: The recombinant fusion protein (HspX–PPE44–EsxV) is produced and then formulated with the Lipo-AE liposomal adjuvant to enhance immune response (Mansury et al., 2019).
Immunization Route: Intramuscular injection (i.m.)
Description: This is a recombinant fusion protein tuberculosis vaccine combining HspX, PPE44, and EsxV antigens with a liposomal adjuvant (Lipo-AE) to enhance T-cell–mediated immune responses and improve protection against Mycobacterium tuberculosis (Mansury et al., 2019).

Host Response

Mouse Response

Host Strain: C57BL/6
Vaccination Protocol: Mice were immunized with 50 ?g antigen on days 0, 14, and 28, with some groups receiving BCG prime at day 0 followed by booster doses of fusion protein or liposome-formulated fusion protein on days 14 and 28 (Mansury et al., 2019).
Efficacy: The vaccinated groups showed significantly reduced bacterial load in lungs and spleen compared to control groups. This indicates enhanced protective immunity against M. tuberculosis infection.(Mansury et al., 2019).
Information about this animal model: Mouse Model for TB research

References

Mansury et al., 2019: Mansury D, Ghazvini K, Amel Jamehdar S, Badiee A, Tafaghodi M, Nikpoor AR, Amini Y, Jaafari MR. Increasing Cellular Immune Response in Liposomal Formulations of DOTAP Encapsulated by Fusion Protein Hspx, PPE44, And Esxv, as a Potential Tuberculosis Vaccine Candidate. Reports of biochemistry & molecular biology. 2019; 7(2); 156-166. [PubMed: 30805395].